Observational studyThe journal of headache and pain2026
Methodology and baseline characteristics of the China Migraine registry (CHIME): a nationwide, multi-center, prospective cohort study of 11,814 patients.
Observational study in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cost-utility analysis of erenumab preventive treatment for chronic migraine in China.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMigraine is the leading cause of years lived with disability (YLDs) in young and middle-aged populations globally. Despite strategic initiatives to standardize headache care in China, large-scale real-world evidence regarding clinical management patterns remains sparse. The China Migraine Registry (CHIME) was established to bridge this gap. This study aims to delineate the CHIME methodology and report the baseline clinical characteristics, diagnostic accuracy, and therapeutic patterns of its initial cohort.
methodsCHIME is a nationwide, multi-center, prospective, longitudinal cohort study involving over 100 specialized headache centers across 28 provinces in China. Initiated in May 2024, the study utilizes a proprietary digital health platform integrated with a clinical decision support system (CDSS 2.0) for headache disorders. Data collection encompasses structured clinical profiles, patient-reported outcomes, and specialized sub-study cores. This baseline analysis details the cross-sectional characteristics of patients enrolled through February 15, 2026.
resultsAmong 11,814 participants (79.43% female; mean age 37.42 ± 10.94 years), 10,123 (85.7%) had episodic migraine (EM), 1,019 (8.6%) had chronic migraine (CM), and 672 (5.7%) had probable migraine. A profound diagnostic-therapeutic gap was identified: only 31.0% of patients had received a correct prior diagnosis. Paradoxically, 91.43% had undergone auxiliary investigations, primarily cranial imaging (87.36%). Acute treatment relied heavily on non-specific analgesics (NSAIDs: 59.77% EM, 51.03% CM). Among patients meeting clinical criteria for prophylaxis, only 26.59% were receiving preventive therapy, and the treatment maintenance rate was critically low (12.56% for ≥3 months). CM patients exhibited significantly higher disability (MIDAS Grade IV: 52.2% vs. 26.9%) and psychiatric comorbidities compared to EM patients (p < 0.001).
conclusionsThe CHIME study reveals a paradoxical "treatment odyssey" in China characterized by a low correct diagnosis rate, pervasive diagnostic over-investigation, alongside a systemic under-utilization of evidence-based therapies. These findings highlight the urgent need for standardized diagnostic implementation and improved prophylactic maintenance in China's headache care system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.